Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
about
Use of thiopurines in inflammatory bowel diseaseThiopurines and inflammatory bowel disease: Current evidence and a historical perspectiveOptimizing the use of thiopurines in inflammatory bowel diseaseGene expression and thiopurine metabolite profiling in inflammatory bowel disease - novel clues to drug targets and disease mechanisms?Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication?6-methylmercaptopurine-induced leukocytopenia during thiopurine therapy in inflammatory bowel disease patients.Use of thiopurines in inflammatory bowel disease: Safety issues.Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease.Review article: acute severe ulcerative colitis - evidence-based consensus statements.Current and emerging drugs for the treatment of inflammatory bowel disease.Combination treatment with 6-mercaptopurine and allopurinol in HepG2 and HEK293 cells - Effects on gene expression levels and thiopurine metabolism.Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease.Weight and Body Composition Compartments do Not Predict Therapeutic Thiopurine Metabolite Levels in Inflammatory Bowel Disease.Optimizing thiopurine therapy in inflammatory bowel disease.Review article: the role of non-biological drugs in refractory inflammatory bowel disease.Inflammatory bowel disease of the elderly: frequently asked questions (FAQs).Recent advances using immunomodulators for inflammatory bowel disease.Management of the elderly patients with inflammatory bowel disease: practical considerations.Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use.The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders.The role of thiopurine metabolite monitoring in inflammatory bowel disease.Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease.Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.Toxicity and response to thiopurines in patients with inflammatory bowel disease.Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease.Low dose thiopurine and allopurinol co-therapy results in significant cost savings at a district general hospital.Effect of azathioprine intolerance on outcomes of inflammatory bowel disease: a cross-sectional study.Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction.Successful Pregnancies with Thiopurine-Allopurinol Co-Therapy for Inflammatory Bowel Disease.Monitoring thiopurine metabolites in inflammatory bowel disease.Azathioprine with Allopurinol: Lower Deoxythioguanosine in DNA and Transcriptome Changes Indicate Mechanistic Differences to Azathioprine Alone.Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis.From pharmacogenetics to pharmacometabolomics: SAM modulates TPMT activity.Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease.Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism.Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations.Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease.
P2860
Q26824662-CADE87BE-5B31-4AC2-80F9-A3924D5C7BAAQ28079644-BB9A32BA-599D-4C30-9CC4-ABD3EEBE8615Q28082687-3FB8047B-F1EA-4B19-8C0D-BAF507532CEDQ28486322-220236AB-F487-49CE-9D15-85961F22949CQ30492009-E1431D42-AED5-44F4-9B25-F5D5A68F869EQ33436894-36103C0A-D070-4E19-AC16-3748ABA57F1CQ33621267-83676F01-8D93-4B9D-B8DD-A1AB3A28A06BQ33654733-D9EEBFAD-B693-4691-84B3-96F41E08B5F8Q34528270-936D768F-6DF0-4C89-B142-EFE8C35D5E81Q34883210-C43AEC6D-4EBE-4DB2-90B5-0A26CFC8FCFDQ36302849-1448F9ED-1F2D-435D-872E-E0A4873513F9Q37570037-D995219D-E9AB-42F7-8027-411DB30FC76BQ37620338-258804C6-95B0-4B03-B4A3-42AE2C74E671Q37800458-B1E8DC8F-5828-425B-A9E8-50127167175EQ37817487-457F6548-F9B4-4D1C-8A03-7BACCEE4B9BAQ37921606-EB7EA302-A3FB-41DF-A3D1-67A5420D53A4Q38081399-E7699599-B8B3-4E06-9508-C6211E85DC7EQ38122069-8BCDFA0C-5792-49FD-9FCE-3DF84BDF27AFQ38179509-46778B59-8E3E-4301-8FF3-BC408A87ABE9Q38195146-8250652A-6601-4B43-A138-9DB52AE1F6DEQ38200692-3DFB5316-22B5-43BC-8FBA-AAAF9D52DEC6Q38253469-AF8DBC83-0841-494F-A276-10A96019D238Q38323592-C6A893AC-6B37-4906-B040-05C4DBF7D630Q38417177-98B5CF5B-99A7-4214-9930-2B1F6951FD83Q38443981-1395D86F-F538-45A9-82D7-637DEA81E2D0Q38563075-51B7C4CA-26CE-46FA-80B6-121B019F089EQ38608975-5472855A-283D-4B02-8624-5DD57B3578D7Q38609051-60F351F2-4841-49EC-947C-F4C361C84D40Q40230618-56309F65-3759-4315-A2B3-6D8246A7AEC8Q40978974-9EC1F0BD-844B-4366-8FC0-3305D483FEB9Q41642129-8CFAA1E3-E227-4430-B3F1-9BE9E6327022Q42257605-03189F89-8731-4199-BA62-0AAA0C535797Q42695266-363A54A5-2E01-4ADE-8A2D-0889CC328285Q43758596-AA344238-A364-49C5-8B4B-A315EDA4D318Q43833709-22C69D6E-ABDD-43B2-98AE-42067191411CQ44316625-A994493D-A364-4040-A7FE-D12D6C9C4D4BQ45552205-70CA1752-B3C3-4321-8BC9-B7DE1B5A465FQ45970071-7A22ABA5-E7D1-4DDB-A217-1BD31C460905Q46283911-A9D76D64-1E32-422E-9C53-7A82AA601F30Q47652468-CAC4D243-69E1-4FB3-95F5-D5742D4E01F6
P2860
Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Low-dose azathioprine or merca ...... th inflammatory bowel disease.
@ast
Low-dose azathioprine or merca ...... th inflammatory bowel disease.
@en
Low-dose azathioprine or merca ...... th inflammatory bowel disease.
@nl
type
label
Low-dose azathioprine or merca ...... th inflammatory bowel disease.
@ast
Low-dose azathioprine or merca ...... th inflammatory bowel disease.
@en
Low-dose azathioprine or merca ...... th inflammatory bowel disease.
@nl
prefLabel
Low-dose azathioprine or merca ...... th inflammatory bowel disease.
@ast
Low-dose azathioprine or merca ...... th inflammatory bowel disease.
@en
Low-dose azathioprine or merca ...... th inflammatory bowel disease.
@nl
P2093
P921
P1476
Low-dose azathioprine or merca ...... th inflammatory bowel disease.
@en
P2093
P304
P356
10.1111/J.1365-2036.2009.04221.X
P407
P577
2009-12-15T00:00:00Z